Previous 10 | Next 10 |
Edwards Lifesciences ( NYSE: EW ) is scheduled to announce Q4 earnings results on Tuesday, January 31st, after market close. The consensus EPS Estimate is $0.61 (+19.6% Y/Y) and the consensus Revenue Estimate is $1.33B (flat Y/Y). Over the last 2 years, EW has beaten EPS est...
The shares of Edwards Lifesciences ( NYSE: EW ) fell more than ~1% pre-market Monday after Piper Sandler downgraded the heart device maker to Neutral from overweight, citing “a less-than-ideal stock set-up.” According to the analyst Adam Maeder, a physician survey in...
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023 PR Newswire IRVINE, Calif. , Jan. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW ) plans to announce its operating results for the quarter ended December 31, 2022 aft...
Summary The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles. To understand where opportunity may lie, I ranked the group according to various financial metrics. Read on to se...
Summary Edwards Lifesciences is a high quality business by any and all measures. Edwards has an excellent financial profile, a history of organic growth as opposed to growth via M&A, and a history of returning cash to shareholders via share repurchases. Now that the earnings mul...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire IRVINE, Calif. , Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference...
Summary Fundsmith’s 13F portfolio value decreased from $23.45B to $21.07B this quarter. They added Otis Worldwide while decreasing Intuit and PayPal Holdings. The top three positions are Microsoft, Philip Morris International, and Estee Lauder, and they add up to ~23% of the ...
Summary Down 40%+ this year, EW is now trading at levels not seen in years. I believe the sell-off is unjust, and investors over the next few months will benefit immensely. This article will cover why past performance almost guarantees continued success. Introduction W...
Summary Wedgewood Partners' 13F portfolio value decreased from $579M to $532M this quarter. They decreased Taiwan Semi and Starbucks during the quarter. Their top five positions are at 36% of the overall portfolio. This article is part of a series that provides an ongoing ...
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877)...
Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program wi...
2024-07-08 19:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...